Shagun Singh
Stock Analyst at RBC Capital
(3.38)
# 931
Out of 4,759 analysts
198
Total ratings
51.76%
Success rate
0.77%
Average return
Main Sectors:
Stocks Rated by Shagun Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Initiates: Outperform | $340 | $251.81 | +35.02% | 1 | Mar 6, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $65 → $55 | $17.96 | +206.24% | 2 | Feb 27, 2025 | |
| MDT Medtronic | Reiterates: Outperform | $105 | $94.50 | +11.11% | 20 | Feb 19, 2025 | |
| PEN Penumbra | Maintains: Outperform | $285 → $313 | $274.79 | +13.91% | 11 | Feb 19, 2025 | |
| JNJ Johnson & Johnson | Reiterates: Outperform | $181 | $166.69 | +8.58% | 17 | Feb 19, 2025 | |
| EW Edwards Lifesciences | Reiterates: Outperform | $85 | $70.33 | +20.86% | 21 | Feb 12, 2025 | |
| INSP Inspire Medical Systems | Reiterates: Outperform | $260 | $183.23 | +41.90% | 4 | Feb 11, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $130 → $125 | $107.99 | +15.75% | 13 | Feb 7, 2025 | |
| BSX Boston Scientific | Maintains: Outperform | $105 → $116 | $99.13 | +17.02% | 14 | Feb 6, 2025 | |
| SYK Stryker | Maintains: Outperform | $425 → $435 | $379.30 | +14.68% | 19 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $135 | $137.14 | -1.56% | 12 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $3 | $0.60 | +400.83% | 9 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $7 | $5.77 | +21.32% | 9 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $92 | $77.41 | +18.85% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $245 | $139.85 | +75.19% | 19 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $115 | $77.84 | +47.74% | 4 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $525 → $555 | $518.26 | +7.09% | 13 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $7.35 | +49.66% | 5 | Oct 8, 2024 |
Insulet
Mar 6, 2025
Initiates: Outperform
Price Target: $340
Current: $251.81
Upside: +35.02%
Tandem Diabetes Care
Feb 27, 2025
Maintains: Outperform
Price Target: $65 → $55
Current: $17.96
Upside: +206.24%
Medtronic
Feb 19, 2025
Reiterates: Outperform
Price Target: $105
Current: $94.50
Upside: +11.11%
Penumbra
Feb 19, 2025
Maintains: Outperform
Price Target: $285 → $313
Current: $274.79
Upside: +13.91%
Johnson & Johnson
Feb 19, 2025
Reiterates: Outperform
Price Target: $181
Current: $166.69
Upside: +8.58%
Edwards Lifesciences
Feb 12, 2025
Reiterates: Outperform
Price Target: $85
Current: $70.33
Upside: +20.86%
Inspire Medical Systems
Feb 11, 2025
Reiterates: Outperform
Price Target: $260
Current: $183.23
Upside: +41.90%
Zimmer Biomet Holdings
Feb 7, 2025
Maintains: Outperform
Price Target: $130 → $125
Current: $107.99
Upside: +15.75%
Boston Scientific
Feb 6, 2025
Maintains: Outperform
Price Target: $105 → $116
Current: $99.13
Upside: +17.02%
Stryker
Jan 29, 2025
Maintains: Outperform
Price Target: $425 → $435
Current: $379.30
Upside: +14.68%
Jan 23, 2025
Reiterates: Outperform
Price Target: $135
Current: $137.14
Upside: -1.56%
Jan 7, 2025
Reiterates: Sector Perform
Price Target: $3
Current: $0.60
Upside: +400.83%
Nov 12, 2024
Reiterates: Sector Perform
Price Target: $7
Current: $5.77
Upside: +21.32%
Nov 6, 2024
Maintains: Outperform
Price Target: $80 → $92
Current: $77.41
Upside: +18.85%
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $245
Current: $139.85
Upside: +75.19%
Oct 25, 2024
Maintains: Outperform
Price Target: $120 → $115
Current: $77.84
Upside: +47.74%
Oct 18, 2024
Maintains: Outperform
Price Target: $525 → $555
Current: $518.26
Upside: +7.09%
Oct 8, 2024
Maintains: Outperform
Price Target: $12 → $11
Current: $7.35
Upside: +49.66%